Summary & Overview
HCPCS J9390: Vinorelbine Tartrate Injection, 10 mg
HCPCS Level II code J9390 denotes a 10 mg unit of vinorelbine tartrate administered by injection, a chemotherapeutic agent used in oncology care. This billing code is important nationally because it standardizes reporting and reimbursement for an injectable cancer drug used across multiple care settings including hospital outpatient departments, physician offices, and infusion centers. Accurate coding supports appropriate payment, inventory tracking, and clinical documentation for cancer treatment.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and comparative coverage context, typical sites of service, and the clinical context for use of vinorelbine as an injectable chemotherapy agent. Where available, payers' coverage practices and reimbursement considerations are summarized to highlight areas that affect billing workflows and payer-provider communications.
The publication provides: an operational overview of the code and service line; common billing considerations tied to chemotherapy drug administration; and the types of documentation and settings in which J9390 is most frequently billed. Data not available in the input are explicitly noted where relevant.
Billing Code Overview
HCPCS Level II code J9390 represents an injection of vinorelbine tartrate, 10 mg. This code is used to bill for administration of the specified chemotherapy agent when provided as an injectable medication.
Service type: Chemotherapy drug administration (injectable oncologic agent)
Typical site of service: Hospital outpatient departments, physician offices, and infusion centers
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9390 is an adult oncology patient diagnosed with non-small cell lung cancer or metastatic breast cancer for whom vinorelbine tartrate is indicated. The patient presents to an outpatient infusion center or hospital oncology infusion clinic for a scheduled intravenous chemotherapy infusion. Prior to administration, the oncology nurse verifies orders, obtains informed consent, reviews baseline labs (complete blood count, hepatic panel), assesses vascular access (peripheral IV or implanted port), and confirms antiemetic and premedication orders. The pharmacist compounds the vinorelbine tartrate vial to the ordered dose (multiples of 10 mg as required), labels the syringe or infusion bag, and documents lot and expiration. During the visit, the nurse monitors vital signs, infusion tolerance, and provides patient education on common adverse effects such as neutropenia, constipation, peripheral neuropathy, and extravasation risk. Billing for the drug is submitted under HCPCS Level II code J9390 with applicable modifiers to indicate circumstances such as the performing provider, service split, discarded drug wastage, or distinct procedural circumstances. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and occasionally inpatient hospital units for patients requiring admission for management or observation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|